Johnson & Johnson News
Most Popular Johnson & Johnson Story
J&J, Bayer report Phase II Xarelto data
Bayer and Johnson & Johnson's presented results from a Phase II study of experimental anti-clotting drug Xarelto (rivaroxaban) at the American Heart Association's annual meeting. The dose-finding... Read more...
Latest Headlines
- November 10, 2008
- October 20, 2008
- September 18, 2008
- August 27, 2008
- August 21, 2008
- August 19, 2008
- August 19, 2008
- July 25, 2008
- June 18, 2008
- June 13, 2008
- November 8, 2007
- September 13, 2007
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
